TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

NCT06001762 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Early-stage Breast Cancer
High Risk Breast Carcinoma

Interventions

DRUG: Abemaciclib
DRUG: Tamoxifen
DRUG: Anastrozole
DRUG: Letrozole
DRUG: Exemestane
DRUG: LHRH Agonist

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]